Attorney Docket: I-2002.015 US

Response to Final Office Action of November 15, 2006

## Amendments to the Claims:

Please replace the pending claims with the claims that follow:

1-29. (cancelled)

30. (withdrawn) An isolated and purified nucleic acid sequence encoding a 30 kD Ostertagia ostertagi protein or a part of said nucleic acid sequence that encodes an immunogenic fragment of said protein, said nucleic acid sequence or said part thereof having at least 85% homology with the nucleic acid sequence of the Ostertagia ostertagi protein gene as depicted in

SEQ ID NO: 9.

31. (withdrawn) A recombinant DNA molecule comprising a nucleic acid sequence according to claim 30, under the control of a functionally linked promoter.

32. (withdrawn) A live recombinant carrier, comprising:

a nucleic acid sequence according to claim 30.

33. (withdrawn) A recombinant host cell, comprising:

a nucleic acid sequence according to claim 30.

Attorney Docket: I-2002.015 US

Response to Final Office Action of November 15, 2006

- 34. (currently amended) An isolated and purified 30 kD Ostertagia ostertagi protein, wherein said protein has [[a]] the sequence as depicted in SEQ ID NO: 10.
- 35. (currently amended) An isolated and purified *Ostertagia ostertagi* protein, wherein said protein is encoded by [[a]] the nucleic acid sequence as depicted in SEQ ID NO: 9.
- 36. (previously presented) A vaccine for combating *Ostertagia ostertagi* infection, comprising the *Ostertagia ostertagi* protein according to claim 34 and a pharmaceutically acceptable carrier.
- 37. (withdrawn) A vaccine for combating *Ostertagia ostertagi* infection, comprising: the nucleic acid sequence according to claims 30, and a pharmaceutically acceptable carrier.
- 38. (withdrawn) A vaccine for combating *Ostertagia ostertagi* infection, comprising: the recombinant host cell according to claim 33 and a pharmaceutically acceptable carrier.
- 39. (withdrawn) A vaccine for combating *Ostertagia ostertagi* infection, comprising: the live recombinant carrier according to claim 32 and a pharmaceutically acceptable carrier.
- 40. (previously presented) The vaccine according to claim 36, further comprising an adjuvant.

Attorney Docket: 1-2002.015 US

Response to Final Office Action of November 15, 2006

41. (withdrawn) The vaccine according to claim 36, further comprising:

an additional antigen derived from a virus or micro-organism pathogenic to cattle, an antibody against said antigen or genetic information encoding said antigen and/or a pharmaceutical component.

- 42. (withdrawn) The vaccine according to claim 41, wherein said virus or microorganism pathogenic to cattle is selected from the group of Bovine Herpesvirus, bovine Viral Diarrhea virus, Parainfluenza type 3 virus, Bovine Paramyxovirus, Foot and Mouth Disease virus, Pasteurella haemolytica, Bovine Respiratory Syncytial Virus, Theileria sp., Babesia sp., Trypanosoma species, Anaplasma sp., Neospora caninum, Staphylococcus aureus, Streptococcus agalactiae, Mycoplasma, E. coli, Enterobacter, Klebsiella, Citrobacter and Streptococcus dysgalactiae.
- 43. (withdrawn) A diagnostic kit, comprising: suitable detection means and a nucleic acid sequence according to claims 30.
- 44. (previously presented) A diagnostic kit, comprising: suitable detection means and a protein according to claim 34.
- 45. (withdrawn) A method of preventing or treating an infection caused by *Ostertagia* ostertagi in an animal, comprising: administering an effective amount of the vaccine according

Attorney Docket: I-2002.015 US

Response to Final Office Action of November 15, 2006

claim 36 to the animal.

46. (withdrawn) A method of preventing or treating an infection caused by Ostertagia

ostertagi in an animal, comprising: administering an effective amount of the vaccine according

claim 37 to the animal.

47. (withdrawn) A method of preventing or treating an infection caused by Ostertagia

ostertagi in an animal, comprising: administering an effective amount of the vaccine according

claim 38 to the animal.

48. (withdrawn) A method of preventing or treating an infection caused by Ostertagia

ostertagi in an animal, comprising: administering an effective amount of the vaccine according

claim 39 to the animal.

49. (withdrawn) A method of preventing or treating an infection caused by Ostertagia

ostertagi in an animal, comprising: administering an effective amount of the vaccine according

claim 41 to the animal.